Kyowa Kirin said on June 26 that it has received Japanese regulatory approval for a new pen-type formulation of its anti-interleukin-17 (IL-17) receptor A antibody Lumicef (brodalumab).The newly approved Lumicef Subcutaneous Injection 210 mg Pen is a prefilled autoinjector containing…
To read the full story
Related Article
- Kyowa Kirin Files Pen Version of Lumicef in Japan
July 1, 2024
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





